Capture réglementaire en temps de pandémie
In the midst of the covid-19 pandemic, the Food and Drug Administration (FDA) published in March the orphan drug status granted to remdesivir, a molecule patented by Gilead as a treatment for the new coronavirus. This gave the company seven years of market exclusivity for its drug in the US market....
Saved in:
Main Author: | Samira Guennif |
---|---|
Format: | Article |
Language: | English |
Published: |
Association Recherche & Régulation
2021-02-01
|
Series: | Revue de la Régulation |
Subjects: | |
Online Access: | https://journals.openedition.org/regulation/17621 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INNOVATIVE PROCESSES IN THE RUSSIAN PHARMACEUTICAL MARKET
by: E. A. Bykova
Published: (2020-09-01) -
A Universal Analysis Pipeline for Hybrid Capture-Based Targeted Sequencing Data with Unique Molecular Indexes
by: Min-Jung Kim, et al.
Published: (2018-12-01) -
Par-delà les temps qui courent : comment la pandémie de covid-19 nous invite à refonder notre rapport au temps
by: Coline Ruwet
Published: (2021-02-01) -
L’Ayurveda
by: Lucie Dejouhanet
Published: (2009-09-01) -
La licence obligatoire : outil emblématique de la protection de la santé publique au Sud
by: Samira Guennif
Published: (2015-06-01)